When Faster IS Better

A WSJ op-ed piece by Richard Miller, an oncologist and the CEO of the Bay Area-based Pharmacyclics, argues that the FDA needs to get cancer drugs to market quicker. Maybe he should direct his eye toward Scottish scientists at the universities of Glasgow and Strathclyde, who are developing a large molecular sensing device they plan to use to test for signature patterns of drug side effects.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.